US Patent Issued to Inhibrx Biosciences on July 22 for "DLL3 single domain antibodies and therapeutic compositions thereof" (California Inventors)

ALEXANDRIA, Va., July 23 -- United States Patent no. 12,365,728, issued on July 22, was assigned to Inhibrx Biosciences Inc. (La Jolla, Calif.).

"DLL3 single domain antibodies and therapeutic compositions thereof" was invented by Brendan P. Eckelman (La Jolla, Calif.), Michael D. Kaplan (La Jolla, Calif.), Katelyn M. Willis (La Jolla, Calif.), Rajay A. Pandit (La Jolla, Calif.), Angelica N. Sanabria (La Jolla, Calif.), Sydney A. Barnes (La Jolla, Calif.), Margaret E. Haerr (La Jolla, Calif.) and John C. Timmer (La Jolla, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are binding polypeptides that specifically bind DLL3. More specifically, provided herein are fusion proteins, including ...